New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
07:37 EDTMYGNMyriad Genetics price target raised to $40 from $28 at Mizuho
Mizuho raised Myriad's price target to $40 from $28 following the better than expected CMS pricing for BRCA testing. Shares are Neutral rated.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
07:11 EDTMYGNMyriad Genetics presented results from myPath Melanoma test clinical study
Subscribe for More Information
September 3, 2014
16:14 EDTMYGNMyriad Genetics says myRisk test improves detection of cancer-causing mutations
Myriad Genetics announced that the Myriad myRisk Hereditary Cancer test significantly improved the detection of cancer-causing mutations by 46% in patients with breast cancer in a new study published in the journal Cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use